EMPLOYMENT STATUS AND HOSPITAL ADMISSIONS AS POTENTIAL MEASURES OF QUALITY OF LIFE FOR PATIENTS UNDERGOING TOTAL PANCREATECTOMY AND ISLET AUTOTRANSPLANTATION

sociodemographic, clinical, and hospital-level factors on overall survival and receipt of definitive treatment for pancreatic cancer.RESULTS: 21,452 Black and Hispanic patients had confirmed diagnoses of non-metastatic pancreatic adenocarcinoma during the study period.Mean age was 66.6 (SD 11.4) years and 45.6% were male.Of those, 4,103 (19.1%) were treated at MSH. Patients treated at MSH were more likely to be male (47.4% vs. 45.2%,p=0.008), to have reported low income (37.8% vs. 32.8%,p<0.001), and to be uninsured (8.6% vs. 3.6%, p<0.001).Patients at MSH were more likely to be diagnosed with stage III disease (28.9% vs. 26.4%,p=0.005), and less likely to be treated at an academic center (41.3% vs 53.2%, p<0.001) when compared to patients treated at non-MSH.There was no difference in the proportion of patients undergoing resection (p=0.353).On adjusted analysis, there was no difference in OS for patients treated at MSH versus those treated at non-MSH (Hazard Ratio [HR] = 0.99, 95% Confidence Interval [CI]:0.95-1.04;p=0.79) (Figure 1).Significant factors associated with a decreased likelihood of death were receipt of surgery (HR 0.44, CI:0.42-0.45),administration of systemic chemotherapy (HR 0.90, 95% CI:0.86-0.94),and high income (HR 0.86, 95% CI:0.80-0.92).In a subgroup analysis of stage I patients, there was no difference in patients undergoing surgical treatment between MSH and non-MSH (odds ratio [OR] = 0.87, 95% CI:0.69-1.09;p=0.23).CONCLUSION: For Black and Hispanic patients with non-metastatic pancreatic cancer, there was no difference in OS associated with receipt of treatment at MSH, despite differences in patient demographics and hospital characteristics.Early-stage patients were equally likely to receive definitive surgical treatment at MSH and non-MSH.Further study is required to identify sources and impact of disparities in cancer care. Tu2037